Publicaciones en colaboración con investigadores/as de Washington University in St. Louis School of Medicine (6)

2023

  1. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

    Breast, Vol. 67, pp. 94-101

  2. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

    Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898

2022

  1. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

    The oncologist, Vol. 27, Núm. 7, pp. e561-e570

2021

  1. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

    Journal of the National Cancer Institute, Vol. 113, Núm. 4, pp. 443-452

2020

  1. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1223-1230

2014

  1. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer

    Journal of Clinical Oncology, Vol. 32, Núm. 32, pp. 3626-3634